Analytical Data
-
Gene name
TRA2A
- Application
-
Alternative Names
AWMS1; HSU53209; htra-2 alpha; Putative MAPK activating Protein PM24; TRA 2 alpha; TRA 2A; TRA-2 alpha; TRA2 alpha; TRA2-alpha; TRA2A; TRA2A_HUMAN; Tra2alpha; Transformer 2 alpha; Transformer 2 Protein homolog; Transformer-2 Protein homolog A; Transformer-2 Protein homolog alpha
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13595
-
Expression Region
2-282 aa
-
AA Sequence
SDVEENNFE GRESRSQSKS PTGTPARVKS ESRSGSRSPS RVSKHSESHS RSRSKSRSRS RRHSHRRYTR SRSHSHSHRR RSRSRSYTPE YRRRRSRSHS PMSNRRRHTG SRANPDPNTC LGVFGLSLYT TERDLREVFS RYGPLSGVNV VYDQRTGRSR GFAFVYFERI DDSKEAMERA NGMELDGRRI RVDYSITKRA HTPTPGIYMG RPTHSGGGGG GGGGGGGGGG GRRRDSYYDR GYDRGYDRYE DYDYRYRRRS PSPYYSRYRS RSRSRSYSPR RY
-
Molecular Weight
32.6 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
TRA2A, or Transformer 2 Alpha, is a crucial splicing factor that plays a significant role in the regulation of gene expression and alternative splicing, particularly in the context of sexual differentiation in various organisms. Research has shown that TRA2A influences the inclusion or exclusion of specific exons in pre-mRNA, thereby affecting the protein isoforms produced, which can have diverse biological functions. The study of TRA2A is particularly relevant in the field of cancer biology, as aberrations in splicing mechanisms are often linked to tumorigenesis. In many cancers, TRA2A expression levels and splicing activity are altered, suggesting a potential role in oncogenesis and providing a possible target for therapeutic intervention. Moreover, TRA2A has been implicated in the progression of neurodegenerative diseases, where dysregulation of splicing can lead to toxic aggregates. The exploration of TRA2A as a recombinant protein has garnered interest, as it allows researchers to examine its functional properties, interaction partners, and downstream effects in a controlled environment. By producing TRA2A in a recombinant system, scientists can investigate its specific roles in splicing regulation and gene expression, while also identifying potential small molecules or inhibitors that could modulate its activity for therapeutic purposes. Understanding the multifaceted roles of TRA2A in various biological processes can provide insights into the underlying mechanisms of diseases and contribute to the development of novel diagnostic and therapeutic approaches.
